Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)

Age
18 years - 55 years
Gender
All
participants needed
10
Location
1
Find a site
Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)

Brief description of study

The research study is being conducted to learn whether an investigational drug called lebrikizumab could impact how effective certain vaccines may be and how effective and safe the study drug is in patients with moderate-to-severe AD compared with placebo. Research procedures include: Physical exam, Medical History, blood and urine tests, study medication and vaccines administered by injection, electronic diary completion and questionnaires.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Atopic Dermatitis,excema
  • Age: 18 years - 55 years
  • Gender: All

Male and Female, Age 15 - 55 Atopic Dermatitis ( excema)

Updated on 04 Aug 2024. Study ID: 845325

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Please provide your preferred way of contact
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center